BioNxt Develops "Melt in Your Mouth" Cladribine for MS Patients

BioNxt Solutions Inc. is advancing a novel cladribine formulation called "Melt in Your Mouth", leveraging its oral dissolvable film (ODF) drug-delivery system. This innovation aims to provide an improved treatment experience for multiple sclerosis (MS) patients, particularly those with dysphagia, or difficulty swallowing. Cladribine, an existing therapy for MS, can be problematic for patients unable to swallow tablets, leading to treatment inconsistencies. BioNxt’s formulation dissolves sublingually and quickly, offering a swallow-free option.

The need for such innovations is highlighted by a meta-analysis showing approximately 45% of MS patients experience swallowing difficulties. The global cladribine market, currently valued at USD 1.2 billion, is projected to grow, alongside oral transmucosal drug-delivery systems. BioNxt's approach targets this expanding market, promising a significant impact on patient adherence and safety.